Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


01.10.2018

2 BJU Int
2 BMC Urol
1 Cancer
2 Cancer Res
1 Clin Cancer Res
3 Eur Urol
4 Int J Cancer
1 Int J Radiat Oncol Biol Phys
1 Int J Urol
1 Nat Rev Urol
1 Oncology (Williston Park)
1 Prog Urol
3 Prostate
2 Urol Int
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. KAYE DR, Qi J, Morgan TM, Linsell S, et al
    Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance.
    BJU Int. 2018 Sep 24. doi: 10.1111/bju.14554.
    PubMed     Text format     Abstract available

  2. CAZZANIGA W, Garmo H, Robinson D, Holmberg L, et al
    Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study.
    BJU Int. 2018 Sep 25. doi: 10.1111/bju.14563.
    PubMed     Text format     Abstract available


    BMC Urol

  3. RAO K, Liang S, Cardamone M, Joshu CE, et al
    Cost implications of PSA screening differ by age.
    BMC Urol. 2018;18:38.
    PubMed     Text format     Abstract available

  4. GROARKE A, Curtis R, Walsh DMJ, Sullivan FJ, et al
    What predicts emotional response in men awaiting prostate biopsy?
    BMC Urol. 2018;18:27.
    PubMed     Text format     Abstract available


    Cancer

  5. JANG TL, Patel N, Faiena I, Radadia KD, et al
    Comparative Effectiveness of Radical Prostatectomy With Adjuvant Radiotherapy Versus Radiotherapy Plus Androgen Deprivation Therapy for Men With Advanced Prostate Cancer.
    Cancer. 2018 Sep 25. doi: 10.1002/cncr.31726.
    PubMed     Text format     Abstract available


    Cancer Res

  6. RUSSO JW, Gao C, Bhasin SS, Voznesensky OS, et al
    Downregulation of Dipeptidyl Peptidase 4 Accelerates Progression to Castration-Resistant Prostate Cancer.
    Cancer Res. 2018 Sep 21. pii: 0008-5472.CAN-18-0687.
    PubMed     Text format     Abstract available

  7. PENFOLD L, Woods A, Muckett P, Nikitin AY, et al
    CAMKK2 promotes prostate cancer independently of AMPK via increased lipogenesis.
    Cancer Res. 2018 Sep 21. pii: 0008-5472.CAN-18-0585.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  8. NAVA RODRIGUES D, Casiraghi N, Romanel A, Crespo M, et al
    RB1 Heterogeneity in Advanced Metastatic Castration Resistant Prostate Cancer.
    Clin Cancer Res. 2018 Sep 26. pii: 1078-0432.CCR-18-2068.
    PubMed     Text format     Abstract available


    Eur Urol

  9. SHINDE A, Li R, Glaser S, Amini A, et al
    Node-positive Nonmetastatic Prostate Cancer: Time to Reconsider Prognostic Staging?
    Eur Urol. 2018 Sep 24. pii: S0302-2838(18)30667.
    PubMed     Text format     Abstract available

  10. TONON L, Fromont G, Boyault S, Thomas E, et al
    Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men.
    Eur Urol. 2018 Sep 20. pii: S0302-2838(18)30618.
    PubMed     Text format     Abstract available

  11. MATTA R, Wallis CJD, Goldenberg MG, Hird AE, et al
    Variation and Trends in Antidepressant Prescribing for Men Undergoing Treatment for Nonmetastatic Prostate Cancer: A Population-based Cohort Study.
    Eur Urol. 2018 Sep 18. pii: S0302-2838(18)30630.
    PubMed     Text format     Abstract available


    Int J Cancer

  12. TSANG SH, Peisch SF, Rowan B, Markt SC, et al
    Association between Trichomonas vaginalis and prostate cancer mortality.
    Int J Cancer. 2018 Sep 22. doi: 10.1002/ijc.31885.
    PubMed     Text format     Abstract available

  13. KRISTENSEN KB, Jensen PH, Skriver C, Friis S, et al
    Use of vitamin K antagonists and risk of prostate cancer: Meta-analysis and nationwide case-control study.
    Int J Cancer. 2018 Sep 24. doi: 10.1002/ijc.31886.
    PubMed     Text format     Abstract available

  14. JI J, Sundquist J, Sundquist K
    Use of terbinafine and risk of death in patients with prostate cancer: A population-based cohort study.
    Int J Cancer. 2018 Sep 27. doi: 10.1002/ijc.31901.
    PubMed     Text format     Abstract available

  15. OMARI A, Nastaly P, Stoupiec S, Balabas A, et al
    Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR and tumor progression in prostate cancer.
    Int J Cancer. 2018 Sep 28. doi: 10.1002/ijc.31905.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  16. MURGIC J, Morton G, Loblaw A, D'Alimonte L, et al
    Focal Salvage High Dose-Rate Brachytherapy for Locally Recurrent Prostate Cancer After Primary Radiation Therapy Failure: Results From a Prospective Clinical Trial.
    Int J Radiat Oncol Biol Phys. 2018;102:561-567.
    PubMed     Text format     Abstract available


    Int J Urol

  17. PATEL DN, Jha S, Howard LE, Amling CL, et al
    Impact of prior local therapy on overall survival in men with metastatic castration-resistant prostate cancer: Results from Shared Equal Access Regional Cancer Hospital.
    Int J Urol. 2018 Sep 25. doi: 10.1111/iju.13806.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  18. LA VECCHIA C
    Early-life alcohol intake and high-grade prostate cancer.
    Nat Rev Urol. 2018 Sep 24. pii: 10.1038/s41585-018-0094.
    PubMed     Text format    


    Oncology (Williston Park)

  19. PATIL T, Bernard B
    Complications of Androgen Deprivation Therapy in Men With Prostate Cancer.
    Oncology (Williston Park). 2018;32.
    PubMed     Text format     Abstract available


    Prog Urol

  20. DELPORTE G, Henon F, Ploussard G, Briganti A, et al
    Radical prostatectomy for locally advanced and high-risk prostate cancer: A systematic review of the literature.
    Prog Urol. 2018 Sep 24. pii: S1166-7087(18)30472.
    PubMed     Text format     Abstract available


    Prostate

  21. JAIN S, Dash P, Minz AP, Satpathi S, et al
    Lipopolysaccharide (LPS) enhances prostate cancer metastasis potentially through NF-kappaB activation and recurrent dexamethasone administration fails to suppress it in vivo.
    Prostate. 2018 Sep 27. doi: 10.1002/pros.23722.
    PubMed     Text format     Abstract available

  22. ROBERTO D, Klotz LH, Venkateswaran V
    Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner.
    Prostate. 2018 Sep 21. doi: 10.1002/pros.23720.
    PubMed     Text format     Abstract available

  23. WANG J, Lu Z, Wu C, Li Y, et al
    Evaluation of the anticancer and anti-metastasis effects of novel synthetic sodium channel blockers in prostate cancer cells in vitro and in vivo.
    Prostate. 2018 Sep 21. doi: 10.1002/pros.23711.
    PubMed     Text format     Abstract available


    Urol Int

  24. AL-BAYATI M, Grueneisen J, Lutje S, Sawicki LM, et al
    Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging.
    Urol Int. 2018;100:164-171.
    PubMed     Text format     Abstract available

  25. SANCHIS-BONET A, Barrionuevo-Gonzalez M, Bajo-Chueca A, Morales-Palacios N, et al
    Does [-2]Pro-Prostate Specific Antigen Meet the Criteria to Justify Its Inclusion in the Clinical Decision-Making Process?
    Urol Int. 2018;100:146-154.
    PubMed     Text format     Abstract available


    Urology

  26. TEELING F, Raison MN, Shabbir MM, Yap MT, et al
    Testosterone therapy for high-risk prostate cancer survivors: a systematic review and meta-analysis.
    Urology. 2018 Sep 20. pii: S0090-4295(18)30993.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: